Pediatric Hematology and Oncology最新文献_第7页

Application of microRNAs in the diagnosis and monitoring of pediatric germ cell tumors: Kazakh experience. 微小RNA在儿童生殖细胞肿瘤诊断和监测中的应用：哈萨克斯坦经验。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2024-01-01 Epub Date: 2024-02-10 DOI: 10.1080/08880018.2023.2267607

Symbat Saliyeva, Riza Boranbayeva, Minira Bulegenova, Vyacheslav Beloussov

引用次数: 0

Can N-acetylcysteine reduce red blood cell transfusion burden in patients with transfusion-dependent β-thalassemia? N- 乙酰半胱氨酸能减轻输血依赖型β地中海贫血患者的红细胞输血负担吗？

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-12-13 DOI: 10.1080/08880018.2023.2292556

Gholamreza Bahoush, Mahdi Rahab, Parnian Ahmadvand

引用次数: 0

Whole genome sequencing and inheritance-based variant filtering as a tool for unraveling missing heritability in pediatric cancer. 全基因组测序和基于遗传的变异过滤作为揭示儿童癌症缺失遗传性的工具。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-05-01 DOI: 10.1080/08880018.2022.2101723

Charlotte Derpoorter, Ruben Van Paemel, Katrien Vandemeulebroecke, Jolien Vanhooren, Bram De Wilde, Geneviève Laureys, Tim Lammens

{"title":"Whole genome sequencing and inheritance-based variant filtering as a tool for unraveling missing heritability in pediatric cancer.","authors":"Charlotte Derpoorter, Ruben Van Paemel, Katrien Vandemeulebroecke, Jolien Vanhooren, Bram De Wilde, Geneviève Laureys, Tim Lammens","doi":"10.1080/08880018.2022.2101723","DOIUrl":"https://doi.org/10.1080/08880018.2022.2101723","url":null,"abstract":"Survival rates for pediatric cancer have significantly increased the past decades, now exceeding 70-80% for most cancer types. The cause of cancer in children and adolescents remains largely unknown and a genetic susceptibility is considered in up to 10% of the cases, but most likely this is an underestimation. Families with multiple pediatric cancer patients are rare and strongly suggestive for an underlying predisposition to cancer. The absence of identifiable mutations in known cancer predisposing genes in such families could indicate undiscovered heritability. To discover candidate susceptibility variants, whole genome sequencing was performed on germline DNA of a family with two children affected by Burkitt lymphoma. Using an inheritance-based filtering approach, 18 correctly segregating coding variants were prioritized without a biased focus on specific genes or variants. Two variants in FAT4 and DCHS2 were highlighted, both involved in the Hippo signaling pathway, which controls tissue growth and stem cell activity. Similarly, a set of nine non-coding variants was prioritized, which might contribute, in differing degrees, to the increased cancer risk within this family. In conclusion, inheritance-based whole genome sequencing in selected families or cases is a valuable approach to prioritize variants and, thus, to further unravel genetic predisposition in childhood cancer.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9437132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic age acceleration among survivors of pediatric medulloblastoma and primitive neuroectodermal tumor. 小儿髓母细胞瘤和原始神经外胚层肿瘤幸存者的表观遗传学年龄加速。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-05-01 Epub Date: 2022-07-21 DOI: 10.1080/08880018.2022.2101722

Rachel D Harris, Melissa A Richard, Maria Monica J Gramatges, Kevin Wilhelm, Michael E Scheurer, Philip J Lupo, Austin L Brown

引用次数: 0

How do you tell parents whose child has cancer that the treatment has failed: A qualitative study on pediatric oncologists' practices. 如何告诉孩子患有癌症的父母治疗已经失败:一项关于儿科肿瘤学家实践的定性研究。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-05-01 DOI: 10.1080/08880018.2022.2120936

Johanna Terrasson, Aude Rault, Étienne Seigneur, Leïla El Mellah, Sylvie Dolbeault, Anne Brédart

{"title":"How do you tell parents whose child has cancer that the treatment has failed: A qualitative study on pediatric oncologists' practices.","authors":"Johanna Terrasson, Aude Rault, Étienne Seigneur, Leïla El Mellah, Sylvie Dolbeault, Anne Brédart","doi":"10.1080/08880018.2022.2120936","DOIUrl":"https://doi.org/10.1080/08880018.2022.2120936","url":null,"abstract":"Announcing drug resistance is complex for pediatric oncologists because they have to provide a substantial amount of medical information while taking a major emotional impact on the parents into account. This study aimed to understand how these announcements are currently conducted and how pediatric oncologists adapt the information given to each family in situations where there is resistance to treatment. Semi-structured interviews were conducted with 15 pediatric oncologists (66.7% women, aged 44.7 years on average). Interviews were audio-recorded and a thematic content analysis was conducted. Announcements of drug resistance are stressful, as they are not well codified, difficult to anticipate, and pediatric oncologists have many issues about how best to behave and which words to choose. The majority of them believe that the severity, or even the incurability of the disease, and the offer of a therapeutic alternative are essential components of the information to pass on. Pediatric oncologists describe how they adapt their communication to each family, particularly in relation to parents' questions, and also to their reactions during the announcement. They also need to adapt to the prior acquaintance they may have with the families, and to previous exchanges. Finally, pediatric oncologists acknowledge their subjectivity when estimating the parents need in terms of information. Understanding the course of these announcements gives us another point of view at the issues involved in this announcement. Proposals to support pediatric oncologists in this difficult moment can be suggested: communication support tool, work in pairs and discussion group.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9380251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Evaluation of pharmacological efficacy and safety of hydroxyurea in sickle cell disease: Study of a pediatric cohort from Chhattisgarh, India. 羟基脲治疗镰状细胞病的药理学疗效和安全性评价:来自印度恰蒂斯加尔邦的一项儿科队列研究

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-05-01 DOI: 10.1080/08880018.2022.2126042

Harsha Lad, Shoma Naskar, S K D B Punyasri Pasupuleti, Rakesh Nahrel, Pradeep Sihare, Giriraj R Chandak, Pradeep K Patra

{"title":"Evaluation of pharmacological efficacy and safety of hydroxyurea in sickle cell disease: Study of a pediatric cohort from Chhattisgarh, India.","authors":"Harsha Lad, Shoma Naskar, S K D B Punyasri Pasupuleti, Rakesh Nahrel, Pradeep Sihare, Giriraj R Chandak, Pradeep K Patra","doi":"10.1080/08880018.2022.2126042","DOIUrl":"https://doi.org/10.1080/08880018.2022.2126042","url":null,"abstract":"Sickle cell disease (SCD) is a disease of abnormal hemoglobin associated with severe clinical phenotype and recurrent complications. Hydroxyurea (HU) is one of the US-FDA approved and commonly used drug for the treatment of adult SCD patients with clinical -severity. However, its use in the pediatric groups remains atypical. Despite a high prevalence of the disease in the state Chhattisgarh, there is a lack of evidence supporting its use in pediatric patients. This study aimed to evaluate the pharmacological and clinical efficacy and safety of HU in a large pediatric cohort with SCD from Central India. The study cohort consisted of 164 SCD (138 Hb SS and 26 Hb S beta-thalassemia) children (≤14 years of age) on HU therapy, who were monitored for toxicity, hematological and clinical efficacy at baseline (Pre-HU) and after 24 months (Post-HU). The results highlight the beneficial effects of HU at a mean dose of 18.7 ± 7.0 mg/kg/day. A significant improvement was observed, not only in physical and clinical parameters but also in hematological parameters which include fetal hemoglobin (Hb F), total hemoglobin, hematocrit, mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) levels, when evaluated against the baseline. We did not observe any significant adverse effects during the treatment period. Similar results were obtained on independent analysis of Hb SS and Hb Sβ patients. These findings strengthen the beneficial effect of hydroxyurea in pediatric population also without any serious adverse effects and builds up ground for expanding its use under regular monitoring.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9380348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

German physicians' perceptions and views on complementary medicine in pediatric oncology: a qualitative study. 德国医生对儿科肿瘤学补充医学的认知和看法:一项定性研究。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-05-01 DOI: 10.1080/08880018.2022.2103218

Pia Klatt, Christin Kohrs, Barbara Stein, Markus Horneber, Daniela Reis, Jan Schildmann, Alfred Längler

{"title":"German physicians' perceptions and views on complementary medicine in pediatric oncology: a qualitative study.","authors":"Pia Klatt, Christin Kohrs, Barbara Stein, Markus Horneber, Daniela Reis, Jan Schildmann, Alfred Längler","doi":"10.1080/08880018.2022.2103218","DOIUrl":"https://doi.org/10.1080/08880018.2022.2103218","url":null,"abstract":"Complementary and alternative medicine (CAM) use in children with cancer has a high prevalence. If (parents of) patients bring up the topic of CAM, pediatric oncologists (POs) face considerable challenges regarding knowledge and professional behavior. In this study, we explore German POs' understanding of CAM and related attitudes as well as challenges and strategies related to CAM discussions by means of semi-structured interviews analyzed according to principles of qualitative thematic analysis with parents of children with cancer. We could conduct 14 interviews prior to theoretical saturation. The interviews had a duration of 15-82 min (M = 30.8, SD = 18.2). Professional experience in pediatric oncology was between 0.5 and 26 years (M = 13.8, SD = 7.6). Main themes identified were a heterogeneous understanding and evaluation of CAM, partly influenced by personal experiences and individual views on plausibility; the perception that CAM discussions are a possible tool for supporting parents and their children and acknowledgement of limitations regarding implementation of CAM discussions; and uncertainty and different views regarding professional duties and tasks when being confronted with CAM as a PO. Our interdisciplinary interpretation of findings with experts from (pediatric) oncology, psychology, and ethics suggests that there is need for development of a consensus on the minimal professional standards regarding addressing CAM in pediatric oncology.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9373897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

SARS-CoV-2 infection and mortality in pediatric patients with hematological malignancies and solid tumors. 小儿血液恶性肿瘤和实体瘤患者的SARS-CoV-2感染和死亡率

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-05-01 DOI: 10.1080/08880018.2022.2120937

João Eduardo Andrade Tavares de Aguiar, Marcos Antônio Lima Carvalho, Simone Santana Viana, Paulo Ricardo Martins-Filho, Rosana Cipolotti

{"title":"SARS-CoV-2 infection and mortality in pediatric patients with hematological malignancies and solid tumors.","authors":"João Eduardo Andrade Tavares de Aguiar, Marcos Antônio Lima Carvalho, Simone Santana Viana, Paulo Ricardo Martins-Filho, Rosana Cipolotti","doi":"10.1080/08880018.2022.2120937","DOIUrl":"https://doi.org/10.1080/08880018.2022.2120937","url":null,"abstract":"The coronavirus disease 2019 (COVID-19) has emerged as a novel cause of mortality among children and adolescents in low- and middle-income settings. 1 In Brazil, deaths from COVID-19 among children and adolescents have exceeded the annual average of deaths from neoplasia, nervous system diseases, cardiac causes, and other vaccine-preventable diseases. 2 It was shown that the overall mortality rate associated with COVID-19 for children and adolescents aged 0–19 up to January 2022 was esti-mated at ∼ 4 deaths per 100,000 children and adolescents, with higher rates registered in the North and Northeast, 3 recognized as the poorest regions in the country. In addition, studies have suggested that immunocompromised children, including those with cancer, are at an increased risk of death from COVID-19 compared to hospitalized children without comorbidities 4 or the general pediatric population. 5 Here, we reported the prevalence of SARS-CoV-2 infection among hospitalized children and adolescents aged 0–21 with cancer and the occurrence of in-hospital deaths associated with COVID-19 in this population. This cross-sectional study was performed from April 2020 to September 2021 at the pediatric oncology center of a tertiary public hospital affiliated to the Brazilian Public Health System ( Sistema Único de Saúde - SUS) in Northeast Brazil. Due to the pandemic of COVID-19, the oncology center has established as a protocol the regular testing for SARS-CoV-2 by RT-PCR of all children undergoing cancer treatment, admitted to the hospital with cancer-related complications, or even with respiratory symptoms suggestive of COVID-19.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9434275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma. 双酶治疗提高戈谢病和尤因肉瘤患者的化疗依从性。

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-05-01 DOI: 10.1080/08880018.2022.2124006

Brandon Lucari, Eran Tallis, Vernon Reid Sutton, Timothy Porea

{"title":"Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma.","authors":"Brandon Lucari, Eran Tallis, Vernon Reid Sutton, Timothy Porea","doi":"10.1080/08880018.2022.2124006","DOIUrl":"https://doi.org/10.1080/08880018.2022.2124006","url":null,"abstract":"This case reports concomitant use of enzyme and substrate reduction therapy to improve chemotherapy adherence in a pediatric patient diagnosed with Ewing sarcoma (ES) and type 1 Gaucher disease (GD). The 17-year-old female presented with 5 months of right knee pain with associated mass on exam. She was diagnosed with ES with pulmonary metastasis. The patient was treated with 17 alternating cycles of vincristine-doxorubicin-cyclophosphamide and ifosfamide and etoposide chemotherapy followed by tumor resection and radiation per standard protocol. As part of her staging work-up, bone marrow biopsy was performed, significant for Gaucher cells. After the second cycle of chemotherapy the patient began to experience severe delays averaging 30 days between cycles compared to 17.29 days observed in Children's Oncology Group data. Given her bone marrow biopsy findings and chemotherapy delays GD screening was obtained and the patient was diagnosed with GD following genetic confirmation. Due to delays in chemotherapy decreasing chance of remission, the patient was referred to Genetics for aggressive management with imiglucerase and eliglustat. After initiation of therapy the period between chemotherapy cycles decreased to 23 days on average, with a 21% increase in platelet count during therapy. The patient was able to complete ES therapy achieving remission. GD is associated with an increased risk of malignancy, as seen in our patient with ES. GD patients experience prolonged hematologic cytopenia during cancer treatment. Combining Enzyme and Substrate Reduction Therapies should be investigated as an option to improve chemotherapy adherence in GD patients.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9734124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Clinical features and prognostic implications of ecotropic viral integration site 1 (EVI1) in childhood acute lymphoblastic leukemia. 儿童急性淋巴细胞白血病中嗜生态病毒整合位点1 (EVI1)的临床特征及预后意义

IF 1.7 4区医学

Pediatric Hematology and Oncology Pub Date : 2023-05-01 DOI: 10.1080/08880018.2022.2117881

Ming Jia, Bo-Fei Hu, Jing-Ying Zhang, Li-Yao Xu, Yong-Min Tang

{"title":"Clinical features and prognostic implications of ecotropic viral integration site 1 (EVI1) in childhood acute lymphoblastic leukemia.","authors":"Ming Jia, Bo-Fei Hu, Jing-Ying Zhang, Li-Yao Xu, Yong-Min Tang","doi":"10.1080/08880018.2022.2117881","DOIUrl":"https://doi.org/10.1080/08880018.2022.2117881","url":null,"abstract":"In contrast to the extensive knowledge on EVI1 in myeloid malignancies, few data are available on the EVI1 transcript in pediatric ALL. The purpose of this study was to examine the clinical and biological significance of EVI1 and validate its prognostic significance in pediatric patients with ALL. Here, we examined the clinical and biological significance of EVI1 expression, as measured by real-time polymerase chain reaction (PCR) in 837 children with newly diagnosed ALL treated on the National Protocol of Childhood Leukemia in China (NPCLC)-ALL-2008 protocol, and aimed to explore their prognostic significance in pediatric ALL patients. The EVI1 expression was detected in 27 of 837 (3.2%) patients. No statistically significant differences in prednisone response, complete remission (CR) rates and relapse rates were found between EVI1 overexpression (EVI1+) group and EVI1- group. Moreover, we found no significant difference in event-free survival (EFS) and overall survival (OS) between these two groups, also multivariate analysis did not identify EVI1+ as an independent prognostic factor. In the subgroup analysis, there was no difference in clinical outcome between EVI1+ and EVI1- patients in standard‑risk (SR), intermediate-risk (IR) and high-risk (HR) groups. In the minimal residual disease (MRD)<10-4 group, EVI1+ patients have significantly lower EFS and OS rates compared to EVI1- patients. Further large‑scale and well‑designed prospective studies are required to confirm the results in the future.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9380257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0